Compare KB Financial Group, Inc. (KB) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Twist Bioscience Corp — how do they compare? KB Financial Group, Inc. trades at $123.07 (market cap $42.62B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: KB Financial Group, Inc. is far larger — about 4.2× Twist Bioscience Corp's market cap, and KB Financial Group, Inc. pays a 2.71% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold KB Financial Group, Inc. for 33 Days and Twist Bioscience Corp for 27 Days on average.
| KB | TWST | |
|---|---|---|
Market Cap | $42.62B | $10.08B |
Volume | 164,291 | 4,229,037 |
Sector | Financials | Health |
52-Week High | $132.88 | $205.00 |
52-Week Low | $77.50 | $25.45 |
Typical Hold Time | 33 Days | 27 Days |
Enterprise Value | $215.53T | $10.01B |
Dividend Yield | 2.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group (KB) trades at $123.07, down 1.33% today, with mixed technical signals showing a neutral overall trend. The company demonstrates strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $3.79 beating expectations of $3.51. Revenue growth has been steady from $17.8T in 2022 to $21.2T in 2025, with net income margins improving to 27.47%. Analyst sentiment is mixed with 33% buy ratings and 67% hold recommendations.
KB presents a compelling value opportunity with a P/E of 9.68 and P/B of 0.94 below industry averages. The main investment thesis centers on continued earnings momentum and South Korean market outperformance, though risks include banking sector volatility and interest rate sensitivity. The stock's current valuation discount to intrinsic value suggests potential upside if earnings growth persists.
Twist Bioscience (TWST) trades at $159.78, up 2.65% today, showing strong momentum despite mixed technical signals. The company continues to demonstrate robust revenue growth, with 2025 revenue reaching $377 million, though profitability remains elusive with a -31.66% net income margin. Recent positive developments include a strategic partnership with Eli Lilly's TuneLab AI platform announced September 16, 2026, driving investor optimism about the company's AI-driven drug discovery capabilities.
While analyst consensus remains bullish with 73% buy ratings, the stock faces significant fundamental challenges including persistent cash burn and negative earnings. The current price exceeds the $145.20 consensus target, suggesting limited near-term upside. Key risks include execution challenges in achieving profitability and dependence on AI partnerships for growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
